MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2

Silvia Pomella1,2, Matteo Cassandri1,3, Lucrezia D'Archivio1

  • 1Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.

Nature Communications
|December 15, 2023
PubMed

Insights

We identified SKP2 as a key driver in fusion-negative rhabdomyosarcomas (FN-RMS). Targeting SKP2 or NEDDylation shows promise for treating this pediatric cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Rhabdomyosarcomas (RMS) are pediatric cancers with distinct subtypes, including Fusion-Negative (FN)-RMS.
  • While MYOD is crucial for RMS survival, it doesn't induce differentiation.
  • FN-RMS often harbors RAS pathway mutations.

Purpose of the Study:

  • To identify novel pro-tumorigenic drivers in FN-RMS.
  • To elucidate the role of SKP2 in FN-RMS pathogenesis.
  • To explore therapeutic vulnerabilities in FN-RMS.

Main Methods:

  • Investigated SKP2 expression and regulation by MYOD in RMS.
  • Assessed the impact of SKP2 depletion on cell cycle, differentiation, and stemness.
  • Utilized the NEDDylation inhibitor MLN4924 to study its effects in FN-RMS models.
  • Evaluated in vivo tumor growth after SKP2 manipulation.

Main Results:

  • Discovered SKP2 overexpression in RMS, driven by MYOD binding to an intronic enhancer.
  • Demonstrated that SKP2 promotes cell cycle progression and inhibits differentiation by targeting p27Kip1 and p57Kip2.
  • SKP2 depletion reactivated myogenic programs, reduced stemness, and inhibited tumor growth.
  • MLN4924 mimicked the effects of SKP2 inhibition.

Conclusions:

  • Established a critical MYOD-SKP2 axis linking transcriptional and post-translational regulation in FN-RMS tumorigenesis.
  • Identified SKP2 as a crucial oncogenic driver in FN-RMS.
  • Highlighted NEDDylation inhibition as a potential therapeutic strategy for FN-RMS.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K